A report from the Joint Economic Committee’s minority arm revealed significant increases in President Donald Trump’s pharmaceutical stock holdings following his return to the White House. The portfolio grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million by the end of 2025. This growth was largely attributed to investments in companies benefiting from exemptions to Medicare’s drug price negotiation program, facilitated by a 2025 tax and spending law.
Investment Details and Timing
Specifically, the report documented purchases totaling up to $2.55 million in shares of pharmaceutical companies with these exemptions, including $950,000 on July 1, 2025, the day the Senate passed the bill, and $1 million in AbbVie stock in August 2025 following the legislation’s enactment. The report highlighted that these exemptions, known as the orphan drug exclusion, allow for continued high prices for certain medications, particularly in areas like cancer treatments.
Impact on Medicare Beneficiaries
Analysis indicated that Medicare beneficiaries receiving medications like nivolumab (Opdivo) and pembrolizumab (Keytruda) could pay approximately $5,000 more annually due to these exemptions. The White House maintains that the portfolio is independently managed and denies any conflicts of interest. The report also noted that a law from President Joe Biden’s administration allowed Medicare to negotiate prices for some of the costliest prescription drugs, while Republicans’ 2025 tax and spending bill expanded the existing exemption, further impacting potential price negotiations.